N-Methyl-N-isopropyltryptamine (MiPT) is a psychedelic tryptamine, closely related to DMT, DiPT and Miprocin.
MiPT base, unlike many other tryptamines in their freebase form, does not decompose rapidly in the presence of light or oxygen.
In August 2019, Chadeayne et al. solved the crystal structure of MiPT fumarate. Its systematic name is [2-(1H-indol-3-yl)ethyl](methyl)propan-2-ylazanium 3-carboxyprop-2-enoate. The salt consists of a protonated tryptammonium cation and a 3-carboxyacrylate (hydrogen fumarate) anion in the asymmetric unit.
10-25 mg is usually taken orally, with effects lasting 4-6 hours.
MiPT is said to emphasize psychedelic/entheogenic effects over sensory/hallucinogenic activity. Users report strong mental effects, but few perceptual alterations.
MiPT is unscheduled in the United States. It may be considered controlled as an analog of another stimulant, alpha-methyl-tryptamine, but this has not been tested in court.